select a format

Single User License
USD 250 INR 16198
Site License
USD 500 INR 32395
Corporate User License
USD 750 INR 48593

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


MedImmune LLC-Pharmaceuticals & Healthcare-Deals and Alliances Profile

MedImmune LLC-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH4960D
  • |
  • Pages: 90
  • |
  • July 2017
  • |
  • |
  Request for Sample Report

Executive Summary

Summary

MedImmune LLC (MedImmune), a subsidiary of AstraZeneca Plc, is a biotechnology company. It focuses on the research, development, manufacture and marketing of small molecules and biologics to address some of the major medical needs. The company develops therapeutic proteins, monoclonal antibodies and other next-generation molecules targeting various diseases. Medimmune undertake research in the areas of cancer treatment; respiratory; inflammation and autoimmune; and cardiovascular disorders and metabolic diseases. It also develops vaccines for the prevention of infectious diseases. The company operates three R&D centers in Gaithersburg, Maryland; Cambridge, the UK; and Mountain View, California. MedImmune is headquartered in Gaithersburg, Maryland, the US.

MedImmune LLC-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 7

MedImmune LLC, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8

MedImmune LLC, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9

MedImmune LLC, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10

MedImmune LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 11

MedImmune LLC, Medical Devices Deals, 2011 to YTD 2017 12

MedImmune LLC, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 13

MedImmune LLC, Pharmaceuticals & Healthcare, Deal Details 17

Venture Financing 17

ADC Therapeutics To Raise USD50 Million In Venture Financing 17

Partnerships 18

MedImmune Enters Into Licensing Agreement With Progenics Pharma For Clostridium Difficile Preclinical Program 18

Sanofi Enters into Co-Development Agreement with MedImmune 19

MedImmune Enters into Co-Development Agreement with Abpro 20

MedImmune Enters into Agreement with Genisphere 21

AstraZeneca and MedImmune Enter into Agreement with University of Michigan and Eli Lilly 21

Cepheid, MedImmune and Combacte Enter into Agreement 22

Rani Therapeutics Enters into Agreement with MedImmune 23

Igenica Biotherapeutics Enters into Research Agreement with MedImmune 24

MedImmune, GlaxoSmithKline and Vanderbilt University Enter into Agreement 25

MedImmune Enters into Research Agreement with University of Sheffield 26

Vall d'Hebron Institute of Oncology Enters into Agreement with AstraZeneca 27

MedImmune Enters into Agreement with Juno Therapeutics 27

MedImmune Enters into Research Agreement with Joslin Diabetes Center 28

MedImmune Enters into Research Agreement with University of Manchester 29

MedImmune Enters into Research Agreement with COEBP 30

MedImmune Enters into Co-Development Agreement with National Cancer Institute 31

Tetragenetics Enters into Agreement with MedImmune for Drug Discovery Program 32

AstraZeneca and MedImmune Enter into R&D Agreement with University of Cambridge 32

Cancer Research UK Forms Joint Venture with MedImmune 34

Advaxis Enters into Agreement with MedImmune 34

MedImmune Enters Into Research Agreement With Cambridge University 35

MedImmune Enters Into Research Agreement With Johns Hopkins University 36

MedImmune Enters Into Co-Development Agreement With ADC Therapeutics 37

MedImmune Enters Into Co-Development Agreement With NGM Biopharma 38

PeptiDream Enters into Drug Discovery Agreement with MedImmune 40

Medimmune Enters Into Research Agreement With Cancer Research Institute And Ludwig Institute for Cancer Research 40

Medimmune And Wuxi Apptec Form Joint Venture To Develop Biologic MEDI5117 For Chinese Market 42

PolyTherics Enters Into Co-Development Agreement With Spirogen For Cancer Drug 43

University Of Michigan Medical School Enters Into Research Agreement With MedImmune 44

AgonOx Enters Into Co-Development Agreement With MedImmune 45

Pfenex Enters Into Collaboration With MedImmune 46

MedImmune Enters Into Co-Development Agreement With Inserm Transfert 47

Licensing Agreements 48

MedImmune Enters into Licensing Agreement with Inovio Pharma 48

Kolltan Pharma Enters into Licensing Agreement with Spirogen 49

Regeneron Pharma Enters into Licensing Agreement with MedImmune 49

MedImmune Enters into Licensing Agreement with Wacker Biotech 50

MedImmune Enters into Licensing Agreement with 3M Drug Delivery Systems 51

Tanabe Research Labs Enters into a Licensing Agreement with MedImmune 52

Daiichi Sankyo Enters into Licensing Agreement with MedImmune for FluMist 53

Shionogi Enters into Licensing Agreement with MedImmune 53

biOasis Enters Into Licensing Agreement With Medimmune For Transcend Brain Delivery Platform 54

MedImmune And Immunocore Enter Into Licensing Agreement To Develop Cancer Therapies 55

Humabs Biomed Enters into Licensing Agreement with MedImmune 56

Biowa And Lonza Enter Into Licensing Agreement With MedImmune For Potelligent CHOK1SV 57

Kolltan Pharma Enters Into Licensing Agreement With MedImmune 58

Axerion Therapeutics Enters Into Licensing Agreement With MedImmune For Alzheimer's Disease 59

MedImmune To Enter Into Licensing Agreement With Pfizer 60

Spirogen Enters Into Licensing Agreement With Genentech 61

Acquisition 62

MedImmune Acquires Definiens for USD150 Million 62

MedImmune Acquires Spirogen From Auven Therapeutics For USD440 Million 63

MedImmune Completes Acquisition Of Amplimmune For Up To USD500 Million 64

MedImmune Acquires AlphaCore Pharma, Cholesterol Drug Developer 66

Ipsen Sells 19.31% Stake In Spirogen, Developer Of DNA Sequence-Targeted Agents 66

MedImmune LLC-Key Competitors 68

Key Employees 69

Locations And Subsidiaries 70

Head Office 70

Other Locations & Subsidiaries 70

Recent Developments 72

Government and Public Interest 72

Jul 06, 2017: New Synthetic DNA-Based Strategy Shows Promise Against a Diverse Range of Influenza Viruses 72

Product News 73

Nov 14, 2016: Inovios Cancer Immunotherapy (INO-3112) Generates T Cell Immune Responses in Tumor Tissue and Peripheral Blood in Patients with HPV-Associated Head and Neck Cancer 73

Aug 23, 2016: IXICO and Cambridge Cluster Study to Detect Early Signs of Alzheimer's Disease 74

Jul 21, 2016: New Study Presents Groundbreaking Pre-clinical work in Developing Immune Therapy 75

Apr 22, 2016: AstraZeneca launches integrated genomics approach to transform drug discovery and development 76

Product Approvals 78

Mar 29, 2017: AstraZenecas potential medicine for neuromyelitis optica spectrum disorder receives orphan designation in Europe 78

Oct 27, 2016: AstraZeneca head and neck cancer trials 79

Mar 09, 2016: AstraZeneca's potential medicine for neuromyelitis optica receives FDA Orphan Drug Designation 80

Mar 07, 2016: Medimmune receives fast track designation in the US for MEDI8852 for treatment of patients hospitalised with influenza A 81

Clinical Trials 82

Jan 18, 2017: Novel Anti-IL-6 Antibody for Rheumatoid Arthritis from WuXi-MedImmune Joint Venture Receives Clinical Trial Permit from CFDA 82

Nov 22, 2016: AstraZeneca head and neck cancer trials resume new patient enrolment as FDA lifts partial clinical hold 83

Sep 06, 2016: Mesothelioma Treatment Center at Baylor St. Luke's launches clinical trial of cancer combination therapy 84

Apr 15, 2016: Preliminary study: Antibody therapy reduces cancer stem cells in multiple myeloma 85

Mar 29, 2016: Inovio Updates INO-3112 HPV Immunotherapy Development Plan 86

Feb 17, 2016: Immune-targeting drug combo shows promise for lung cancer patients, says Moffitt 87

Feb 08, 2016: Astrazeneca'S Combination Of Durvalumab With Tremelimumab Shows Clinical Activity In Non-Small Cell Lung Cancer Irrespective Of PD-L1 Status 88

Appendix 90

Methodology 90

About GlobalData 90

Contact Us 90

Disclaimer 90

List of Figures

MedImmune LLC, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

MedImmune LLC, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

MedImmune LLC, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

MedImmune LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

MedImmune LLC, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8

MedImmune LLC, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 9

MedImmune LLC, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10

MedImmune LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 11

MedImmune LLC, Medical Devices Deals, 2011 to YTD 2017 12

List of Tables

MedImmune LLC, Pharmaceuticals & Healthcare, Key Facts 1

MedImmune LLC, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8

MedImmune LLC, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9

MedImmune LLC, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10

MedImmune LLC, Deals By Therapy Area, 2011 to YTD 2017 11

MedImmune LLC, Medical Devices Deals, 2011 to YTD 2017 12

MedImmune LLC, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 13

ADC Therapeutics To Raise USD50 Million In Venture Financing 17

MedImmune Enters Into Licensing Agreement With Progenics Pharma For Clostridium Difficile Preclinical Program 18

Sanofi Enters into Co-Development Agreement with MedImmune 19

MedImmune Enters into Co-Development Agreement with Abpro 20

MedImmune Enters into Agreement with Genisphere 21

AstraZeneca and MedImmune Enter into Agreement with University of Michigan and Eli Lilly 21

Cepheid, MedImmune and Combacte Enter into Agreement 22

Rani Therapeutics Enters into Agreement with MedImmune 23

Igenica Biotherapeutics Enters into Research Agreement with MedImmune 24

MedImmune, GlaxoSmithKline and Vanderbilt University Enter into Agreement 25

MedImmune Enters into Research Agreement with University of Sheffield 26

Vall d'Hebron Institute of Oncology Enters into Agreement with AstraZeneca 27

MedImmune Enters into Agreement with Juno Therapeutics 27

MedImmune Enters into Research Agreement with Joslin Diabetes Center 28

MedImmune Enters into Research Agreement with University of Manchester 29

MedImmune Enters into Research Agreement with COEBP 30

MedImmune Enters into Co-Development Agreement with National Cancer Institute 31

Tetragenetics Enters into Agreement with MedImmune for Drug Discovery Program 32

AstraZeneca and MedImmune Enter into R&D Agreement with University of Cambridge 32

Cancer Research UK Forms Joint Venture with MedImmune 34

Advaxis Enters into Agreement with MedImmune 34

MedImmune Enters Into Research Agreement With Cambridge University 35

MedImmune Enters Into Research Agreement With Johns Hopkins University 36

MedImmune Enters Into Co-Development Agreement With ADC Therapeutics 37

MedImmune Enters Into Co-Development Agreement With NGM Biopharma 38

PeptiDream Enters into Drug Discovery Agreement with MedImmune 40

Medimmune Enters Into Research Agreement With Cancer Research Institute And Ludwig Institute for Cancer Research 40

Medimmune And Wuxi Apptec Form Joint Venture To Develop Biologic MEDI5117 For Chinese Market 42

PolyTherics Enters Into Co-Development Agreement With Spirogen For Cancer Drug 43

University Of Michigan Medical School Enters Into Research Agreement With MedImmune 44

AgonOx Enters Into Co-Development Agreement With MedImmune 45

Pfenex Enters Into Collaboration With MedImmune 46

MedImmune Enters Into Co-Development Agreement With Inserm Transfert 47

MedImmune Enters into Licensing Agreement with Inovio Pharma 48

Kolltan Pharma Enters into Licensing Agreement with Spirogen 49

Regeneron Pharma Enters into Licensing Agreement with MedImmune 49

MedImmune Enters into Licensing Agreement with Wacker Biotech 50

MedImmune Enters into Licensing Agreement with 3M Drug Delivery Systems 51

Tanabe Research Labs Enters into a Licensing Agreement with MedImmune 52

Daiichi Sankyo Enters into Licensing Agreement with MedImmune for FluMist 53

Shionogi Enters into Licensing Agreement with MedImmune 53

biOasis Enters Into Licensing Agreement With Medimmune For Transcend Brain Delivery Platform 54

MedImmune And Immunocore Enter Into Licensing Agreement To Develop Cancer Therapies 55

Humabs Biomed Enters into Licensing Agreement with MedImmune 56

Biowa And Lonza Enter Into Licensing Agreement With MedImmune For Potelligent CHOK1SV 57

Kolltan Pharma Enters Into Licensing Agreement With MedImmune 58

Axerion Therapeutics Enters Into Licensing Agreement With MedImmune For Alzheimer's Disease 59

MedImmune To Enter Into Licensing Agreement With Pfizer 60

Spirogen Enters Into Licensing Agreement With Genentech 61

MedImmune Acquires Definiens for USD150 Million 62

MedImmune Acquires Spirogen From Auven Therapeutics For USD440 Million 63

MedImmune Completes Acquisition Of Amplimmune For Up To USD500 Million 64

MedImmune Acquires AlphaCore Pharma, Cholesterol Drug Developer 66

Ipsen Sells 19.31% Stake In Spirogen, Developer Of DNA Sequence-Targeted Agents 66

MedImmune LLC, Key Competitors 68

MedImmune LLC, Key Employees 69

MedImmune LLC, Other Locations 70

MedImmune LLC, Subsidiaries 71

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

MedImmune LLC, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.


Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com